News
-
-
-
COMMUNIQUÉ DE PRESSE
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Jaguar Health, Inc. announces virtual event on crofelemer clinical development efforts for rare diseases MVID and SBS-IF. CEO awarded 'Best CEO BioPharmaceuticals of the Year' -
-
-
COMMUNIQUÉ DE PRESSE
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals presents statistically significant results of crofelemer in breast cancer patients for prophylaxis of CTD at SABCS. Study highlights impact of diarrhea in cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Jaguar Health's Napo Pharmaceuticals to present data on crofelemer in breast cancer patients at SABCS 2024. Additional analyses ongoing. Patient advocacy program also announced -
